Alagene is a next-generation synthetic biology CRO and biofoundry based in Rehovot, Israel. We provide end-to-end R&D services that help biotech companies accelerate development of microbial-based products from early concept to scalable, production-ready processes. Our integrated platform combines microbial strain engineering (bacteria, yeast, and fungi), custom bioassay development, high-throughput screening, fermentation optimization, downstream process development, and advanced analytics. By operating these capabilities under one roof, Alagene eliminates fragmented workflows and reduces technical and commercial risk. A core differentiator of Alagene is our techno-economic design (TEA) approach, which embeds cost-of-goods considerations directly into R&D decision-making. This enables our partners to optimize not only biological performance but also economic viability early in development. Alagene works with startups, multinational corporates, and academic groups across food-tech, ag/clean-tech, aquaculture, cosmetics, industrial biotech, and biopharma. The company operates as a flexible partner, offering fee-for-service, milestone-based, and licensing-oriented collaboration models. Alagene is owned by HyLabs group, Israel’s leading biotechnology services organization, providing access to robust infrastructure and operational expertise.